Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Europe

Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.

You may also be interested in...



People In The News: Tracking The Latest Industry Personnel Moves

Presidents & CEOs

People In The News: Tracking The Latest Industry Personnel Moves

Presidents & CEOs

Vertex Takes Early Lead In HCV Protease Inhibitor Sales

Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.

Table

View full table

Related Content

In Vivo
Pink Sheet

Topics

Tags:
BioPharmaceutical Europe
Latest Headlines

US WorldMeds’ Eflornithine Gets US FDA Panel Nod For Pediatric Neuroblastoma

US FDA Versus Its Own Precedents

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

New ePortal To Simplify Processing & Tracking Of WHO Prequalification Applications

See All
UsernamePublicRestriction

Register

PS072753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By